A Hold recommendation has recently been issued to healthcare company Cyclacel Pharmaceuticals, Inc. (CYCC) by Zacks senior healthcare analyst Grant Zeng, CFA.  Here's what his latest update said:

'Cyclacel Pharmaceuticals, Inc. is a clinical stage company dedicated to the discovery, development and commercialization of small molecule cell cycle inhibitors for the treatment of cancers and other serious disorders. The company's lead pipeline candidate, CYC202, is being developed for the treatment of non-small cell lung cancer. The recent acquisition of Align has bolstered the company's oncology/hematology programs and provided it with a revenue stream.

'However, CYC202, as well as other pipeline candidates, are still in early or mid-stage development process. Although we believe the development of CYC202 for the third-line treatment of NSCLC presents a significant commercial opportunity for the company, it is still several years away from reaching the market.

'Cyclacel offers development programs in cancer, type II diabetes, inflammatory kidney diseases, and viral infections. We would like to see more results on the CYC202 candidate before recommending the stock. As such, we maintain our Hold rating with a target price of $6.00.'